Enoxaparin versus control for venous thromboembolic prophylaxis after total knee arthroplasty in Asian patients: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20140527001

Enrollment

Registered

2014-05-27

Start date

2014-05-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis of knee knee arthroplasty DVT prophylaxis

Interventions

enoxaparin 40 mg subcutaeous once a day start from 24 hour postoperative to 7 to 10 days

Experimental Drug

enoxaparin

Eligibility

Sex/Gender

All

Age

55 Years to 90 Years

Inclusion criteria

Inclusion criteria: patients with diagnosis of osteoarthritis of knee who underwent total knee arthroplasty

Exclusion criteria

Exclusion criteria: patient with abnormal bleeding patient without discontinuation of antiplatelet drug 7 days before surgery patient with history of deep vein thrombosis

Design outcomes

Primary

Measure	Time frame
thromboembolic evet 6 to 10 days after surgery doppler ultrasound,major bleeding 3 and 7 days after surgery hematoma grading scale	—

Secondary

Measure	Time frame
total blood loss 3 and 7 days after surgery record blood loss intra and postoperative	—

Countries

Thailand

Contacts

Public ContactTawan Intiyanaravut

Golden Jubilee Medical Center

tawan.int@mahidol.ac.th028496600

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026